{"id":"NCT03572933","sponsor":"Marinus Pharmaceuticals","briefTitle":"Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder","officialTitle":"A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-30","primaryCompletion":"2020-07-31","completion":"2021-05-28","firstPosted":"2018-06-28","resultsPosted":"2022-07-26","lastUpdate":"2023-04-14"},"enrollment":101,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["CDKL5 Deficiency Disorder"],"interventions":[{"type":"DRUG","name":"ganaxolone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo (for ganaxolone)"]}],"arms":[{"label":"Ganaxolone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in children and young adults with genetically confirmed CDKL5 gene mutation.","primaryOutcome":{"measure":"Summary of 28-day Seizure Frequency for Major Motor Seizure Types","timeFrame":"End of the double-blind 17 week treatment period","effectByArm":[{"arm":"Placebo","deltaMin":49.17,"sd":null},{"arm":"Ganaxolone","deltaMin":54,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":36,"countries":["United States","Australia","France","Israel","Italy","Poland","Russia","United Kingdom"]},"refs":{"pmids":["36517284","35429480"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":51},"commonTop":["Somnolence","Seizure","Vomiting","Pyrexia","Upper Respiratory Tract Infection"]}}